Abstract
When disease transmission can precede symptom onset, containing outbreaks requires distinct strategies, like active surveillance. Yet it is rarely clear in advance when such interventions are needed, especially for emerging pathogens. Predicting pre-symptomatic transmission would be easier with knowledge of the within-host dynamics that enable pre-symptomatic transmission. To investigate those dynamics, we survey controlled human infection (CHI) trials with viral agents, which contain data on incubation times, infection duration, and transmission potential following inoculation with a known dose. We find that all studies report information on the duration of viral shedding, but few report the timing of symptoms. Only one study provided data on the timing of shedding and symptoms for individual participants, following norovirus inoculation. We apply a statistical model to individual time series to show significantly greater potential for pre-symptomatic transmission with faster viral replication, but no evidence for a tradeoff between transmission rate and duration during the pre-symptomatic phase. We then compare within-host models of pathogen replication, immune clearance, and symptom onset to identify plausible assumptions about the causes of pre-symptomatic transmission. We recover the pattern that peak shedding can precede symptom onset if we assume that symptoms are triggered by immune responses rather than pathogen abundance. Only by relaxing the standard assumption of exponential growth can we recover the pattern that faster viral replication enables pre-symptomatic transmission. Thus, data on symptom onset in CHI trials, paired with models, can illuminate the within-host dynamics underpinning pre-symptomatic transmission, guiding efforts to improve control strategies.
Significance statement The COVID-19 pandemic was exacerbated by the potential for transmission before symptoms. Yet the causes of pre-symptomatic transmission remain unclear, hindering efforts to predict disease spread and tailor control efforts for novel pathogens. For known pathogens, the potential for pre-symptomatic transmission varies across individuals, but patterns may emerge from controlled human infection (CHI) trials. We surveyed CHI trials, finding that only one reported data on individual participants. We fit a simple model to those data, finding that faster viral replication correlates with pre-symptomatic transmission. We used more detailed models to identify plausible assumptions about the causes of symptom onset, e.g., that immune responses trigger symptoms. Thus, applying models to CHI trial data gives insight into the drivers of pre-symptomatic transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Cornell University College of Agricultural Sciences and the Cornell Institute of Host-Microbe Interactions & Disease Undergraduate Research Experience.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human viral shedding and symptom onset/duration data originally located at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2609865/. We used data from Table 1 as well as Figures 1C-E.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Full code to mine data and reproduce analyses and figures is available at https://github.com/greischarlab/transmission-modeling.
